Advertisement

Advertisement

Breast Cancer
Issues in Oncology

Younger vs Older Women With Breast Cancer: Understanding the Differences

Younger women with breast cancer differ from their older counterparts in ways that should be appreciated by their clinicians, according to Ann H. Partridge, MD, MPH, FASCO, Vice Chair of Medical Oncology at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. At PER’s...

Breast Cancer

I Want to Live Long and I Want to Live Well

I’m a person who doesn’t like uncertainty. I’m also a worrier. So, when my hand kept going to the same spot on the upper part of my left breast near my chest wall, I couldn’t shake the feeling that something wasn’t quite right, which persisted even after a routine mammography failed to find any...

Breast Cancer
Genomics/Genetics

Breast Cancer Susceptibility Genes: Putting the Pieces Together

With the widespread use of multigene panels for germline genetic testing, understanding the cancer risks associated with pathogenic or likely pathogenic variants (ie, mutations) has become increasingly necessary. To identify which genes are breast cancer susceptibility genes, population studies...

Breast Cancer
Genomics/Genetics

U.S. Population–Based Study of Prevalence of and Risk Associated With Breast Cancer–Predisposition Genes

In a U.S. population–based, case-control study reported in The New England Journal of Medicine, Chunling Hu, MD, PhD, of the Mayo Clinic, Rochester, Minnesota, and colleagues identified the prevalence of and breast cancer risk associated with germline pathogenic variants in established and...

Breast Cancer
Lung Cancer
Global Cancer Care

Female Breast Cancer Surpasses Lung Cancer as the Most Commonly Diagnosed Cancer Worldwide

Cancer ranks as a leading cause of death in every country in the world, and, for the first time, female breast cancer is the most commonly diagnosed cancer, overtaking lung cancer, according to a collaborative report from the American Cancer Society (ACS) and the International Agency for Research...

Breast Cancer

Development of Oral Taxane Tesetaxel to Be Discontinued

Following feedback from the U.S. Food and Drug Administration (FDA) in a pre–new drug application meeting, Odonate Therapeutics has concluded that the clinical data package for tesetaxel, an oral taxane tested in patients with metastatic breast cancer, is unlikely to support FDA approval....

Breast Cancer

Distant Metastasis–Free Survival With Adjuvant vs No Adjuvant Chemotherapy According to Genomic and Clinical Risk in Early Breast Cancer

In an updated analysis of the European phase III MINDACT trial reported in The Lancet Oncology, Martine Piccart, MD, and colleagues found confirmatory evidence of the initial finding of a high rate of distant metastasis–free survival among patients with high–clinical-risk but low–genomic-risk...

Breast Cancer

No Benefit Found for Everolimus Plus Adjuvant Hormone Therapy in High-Risk Early-Stage Breast Cancer

Everolimus plus hormone therapy improves outcomes in the advanced disease setting but apparently not in the adjuvant setting, according to the results of the UNIRAD trial, presented as a part of the European Society for Medical Oncology (ESMO) Virtual Plenary program.1 “In the UNIRAD study, after...

Breast Cancer
COVID-19

Time to Treatment Initiation for Breast Cancer During the COVID-19 Pandemic: Single-Institution Study

In a single-institution study reported in JCO Oncology Practice, Hawrot et al found that there was no increase in time to treatment initiation after histologic diagnosis in patients with newly diagnosed breast cancer during the first wave of the COVID-19 pandemic in 2020. However, they did find...

breast cancer
immunotherapy

William J. Gradishar, MD, on Triple-Negative Breast Cancer: NCCN Guidelines Update

William J. Gradishar, MD, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the latest recommendations from the National Comprehensive Cancer Network for treating patients with triple-negative breast cancer; data on early-stage and advanced disease; and the role of checkpoint inhibitors, antibody-drug conjugates, and PARP inhibitors.

Breast Cancer

DCIS Biologic Risk Signature May Predict Risk of Recurrence and Radiation Benefit After Breast-Conserving Surgery

Women with ductal carcinoma in situ (DCIS) and elevated decision scores had a significantly higher risk of ipsilateral breast events and a greater relative benefit from radiation therapy compared to women with lower decision scores, according to research presented by Mann et al at the Society of...

Breast Cancer

Improving the Prognostic Accuracy of Residual Cancer Burden After Neoadjuvant Chemotherapy for Breast Cancer

An analysis of 546 patients with breast cancer who received neoadjuvant chemotherapy demonstrated that residual cancer burden is prognostic for overall survival, recurrence-free survival, and distant relapse­–free survival, according to research presented by White et al at the Society of Surgical...

Breast Cancer
Immunotherapy

Pembrolizumab vs Chemotherapy in Previously Treated Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-119

As reported in The Lancet Oncology by Eric P. Winer, MD, FASCO, and colleagues, the phase III KEYNOTE-119 trial showed no significant improvement in overall survival with pembrolizumab vs investigator’s choice of chemotherapy in the second- or third-line treatment of metastatic triple-negative...

Breast Cancer

Persistent Use of Low-Value Breast Cancer Surgeries Designated for Deimplementation by Choosing Wisely

In a retrospective cohort study reported in JAMA Surgery, Wang et al found persistent use of low-value breast cancer surgeries designated for deimplementation by the Choosing Wisely program, with a wide interfacility variation in use of these procedures. Study Details The study used National Cancer ...

Breast Cancer
Immunotherapy

Novel HER2-Targeted Therapies Pose Sequencing Challenges

With three new HER2-targeted therapies approved in the past 15 months alone, the treatment landscape for patients with metastatic breast cancer has become increasingly crowded. In the third-line setting and beyond, there are now at least eight HER2-targeted agents approved by the U.S. Food and Drug ...

Breast Cancer

Study Finds Regularly Drinking Sugar-Sweetened Soda May Increase Total and Breast Cancer Mortality

New research published by Koyratty et al in Cancer Epidemiology, Biomarkers & Prevention suggests that patients with breast cancer who drink sugar-sweetened beverages regularly are at increased risk for death from any cause, and from breast cancer in particular. Compared to women who never or...

Breast Cancer
Bladder Cancer
Gastrointestinal Cancer
Hepatobiliary Cancer
Lung Cancer
Immunotherapy

FDA Oncologic Drugs Advisory Committee to Review Status of Six Indications Granted Accelerated Approval

Recently, the U.S. Food and Drug Administration (FDA) announced that the agency will hold a public meeting of the Oncologic Drugs Advisory Committee on April 27 to 29 to discuss six indications granted accelerated approval that have since reported results from confirmatory trials that have not...

Breast Cancer

Older Breast Cancer Survivors May Consider Discontinuing Screening Mammography in the Setting of Limited Life Expectancy

Newly issued mammography screening guidelines for breast cancer survivors aged 75 and older recommend discontinuing routine mammography for those with a life expectancy of less than 5 years and considering discontinuation of routine screening for those with a life expectancy between 5 and 10 years. ...

Breast Cancer

Miami Breast Cancer Conference: Genomic Assays Show Utility in Predicting Pathologic Complete Response Rate in Pre- and Postmenopausal Patients With Breast Cancer

New data from the prospective Neoadjuvant Breast Symphony Trial (NBRST), which demonstrated the predictive and prognostic abilities of the MammaPrint and BluePrint assays and underpinned their preoperative utility in pre-and postmenopausal patients with breast cancer, were presented at PER’s Miami...

Breast Cancer
Immunotherapy

Miami Breast Cancer Conference: Updated DESTINY-Breast01 Results Show Trastuzumab Deruxtecan-nxki Delivers Durable Responses

In updated results from the pivotal DESTINY-Breast01 trial, trastuzumab deruxtecan-nxki (T-DXd) demonstrated high rates of durable responses consistent with prior results, with encouraging progression-free survival and overall survival in patients with HER2-positive metastatic breast cancer. These...

Breast Cancer
Global Cancer Care

New Global Breast Cancer Initiative Highlights Renewed Commitment to Improve Survival

A major new collaborative effort, the Global Breast Cancer Initiative, was introduced by the World Health Organization (WHO), with the objective of reducing global breast cancer mortality by 2.5% per year until 2040, thereby averting an estimated 2.5 million deaths.  In recognition of International ...

Breast Cancer

Outcomes With Internal Mammary and Medial Supraclavicular Nodal Irradiation in Stage I to III Breast Cancer

As reported in The Lancet Oncology by Philip M. Poortmans, PhD, Department of Radiation Oncology of the Iridium Netwerk and the Faculty of Medicine and Health Sciences, University of Antwerp, and colleagues, 15-year outcomes of the phase III EORTC 22922/10925 trial show continued reduction in...

Breast Cancer
Genomics/Genetics

Salpingo-Oophorectomy to Reduce Ovarian Cancer Risk in Women With BRCA1 or BRCA2 Pathogenic Variants May Also Reduce Breast Cancer Risk

In a study reported in JAMA Oncology, Choi et al found that risk-reducing salpingo-oophorectomy in women with BRCA1 or BRCA2 pathogenic variants was associated with a reduced risk of breast cancer within 5 years after surgery, with evidence of longer-term risk reduction among those with BRCA1...

Breast Cancer
Global Cancer Care

Increase in Diagnosis of Node-Positive and Stage III Breast Cancer After Screening Interruption Due to the COVID-19 Pandemic

A new report from Italy published by Toss et al in ESMO Open noted an increase in diagnoses of node-positive and stage III breast cancer after a 2-month interruption in breast cancer screening due to the COVID-19 pandemic. These findings support recommendations for a quick restoration of breast...

Breast Cancer
Issues in Oncology

Adherence to Adjuvant Hormonal Therapy Among Commercially Insured Women With Breast Cancer

In a study reported in JCO Oncology Practice, Zhao et al found that 5-year adherence to adjuvant hormonal therapy was low among commercially insured women with breast cancer in the United States. The retrospective observational study used data from the IBM MarketScan Research Databases to identify...

Breast Cancer

Miami Breast Cancer Conference: Study Examines Response to Neoadjuvant Chemotherapy in Hispanic and Black Patients

Few studies documenting the benefit of neoadjuvant chemotherapy for breast cancer have been conducted in minority populations. A single-institution study reported at PER's Miami Breast Cancer Conference, held virtually this year, confirmed that neoadjuvant chemotherapy improved axillary disease in...

Breast Cancer
Global Cancer Care

Effect of Clinical Breast Examination Screening on Stage at Diagnosis and Breast Cancer Mortality

In an Indian study reported in the British Medical Journal, Mittra et al found that breast cancer screening with clinical breast examination vs active surveillance resulted in younger age and significant downstaging of disease at diagnosis of breast cancer, a significant reduction in breast cancer...

Breast Cancer

Study Finds Missing Annual Mammogram Increases Risk of Death From Breast Cancer

Regular mammography screening substantially reduces the risk of dying from breast cancer, according to a large study of over half a million women published by Stephen W. Duffy, MSc, and colleagues in the journal Radiology. Researchers said women who skipped even one scheduled mammography screening...

Breast Cancer

Updates From Selected Clinical Trials in Breast Cancer

Each year, following the San Antonio Breast Cancer Symposium (SABCS), The ASCO Post asks Jame Abraham, MD, FACP, to offer his picks of the most important and most clinically relevant research presented at this meeting. The following are summaries of studies that caught Dr. Abraham’s attention from ...

Breast Cancer

PHOEBE Trial: Pyrotinib/Capecitabine vs Lapatinib/Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab

In a prespecified interim analysis of the Chinese phase III PHOEBE trial reported in The Lancet Oncology, Xu et al found that the combination of the irreversible pan-HER inhibitor pyrotinib plus capecitabine significantly prolonged progression-free survival vs lapatinib plus capecitabine in...

Breast Cancer
Immunotherapy

I Let Science, Not Emotion, Dictate My Treatment

I had my first experience with cancer when I was just 3 or 4 years old and complained to my mother that my “tummy hurt.” I was diagnosed with Wilms tumor, the same cancer my 18-month-old brother died of before I was born. I remember being in the hospital for weeks at a time and being known by...

Breast Cancer

The CARG-BC Score: Novel Tool for Predicting Chemotherapy Toxicity in Early-Stage Breast Cancer

As reported in the Journal of Clinical Oncology, Allison Magnuson, DO, of the University of Rochester Medical Center & Wilmot Cancer Institute, and Mina S. Sedrak, MD, MS, of the City of Hope National Medical Center, along with colleagues, have developed a novel risk tool—the Cancer and Aging...

Breast Cancer

Prognostic Tool RSClin Introduced for Early Breast Cancer

Data from the TAILORx study and several National Surgical Adjuvant Breast and Bowel Project (NSABP) trials have been used to develop a new prognostic tool, RSClin, which aims to individualize the estimate of recurrence risk in early breast cancer and to more accurately predict the risk-reduction...

Breast Cancer
Survivorship

Can Weight Loss During Treatment and Follow-up Affect Breast Cancer Outcomes?

Research published by Martel et al in JNCCN—Journal of the National Comprehensive Cancer Network examined body mass index (BMI) data for patients with HER2-positive early breast cancer—and found a 5% weight loss in patients over 2 years was associated with worse outcomes. Weight gain over the same...

Breast Cancer
Gynecologic Cancers
Genomics/Genetics

Trends in Germline Genetic Testing in Women Diagnosed With Breast or Ovarian Cancer

In a study of germline genetic testing in women diagnosed with breast or ovarian cancer reported in the Journal of Clinical Oncology, Allison W. Kurian, MD, MSc, and colleagues found that undertesting persists in patients with ovarian cancer, and that most pathogenic variants are found in 20 breast ...

Breast Cancer
Immunotherapy

Addition of Adjuvant Pertuzumab to Chemotherapy Plus Trastuzumab in Early HER2-Positive Breast Cancer: 6-Year Follow-up of the APHINITY Trial

As reported in the Journal of Clinical Oncology by Martine Piccart, MD, PhD, and colleagues, the preplanned second interim analysis of overall survival in the phase III APHINITY trial showed no significant benefit of the addition of adjuvant pertuzumab to chemotherapy plus trastuzumab after a...

Breast Cancer

Have Breast Cancer Mortality Rates Stopped Declining for Younger Women?

Breast cancer death rates have stopped declining for women in the United States younger than age 40, ending a trend that existed from 1987 to 2010, according to a report published by Hendrick et al in Radiology. Breast cancer is the most common nonskin cancer and the second most common cause of...

Breast Cancer

Elacestrant for Heavily Pretreated Patients With ER-Positive, HER2-Negative Metastatic Breast Cancer

In a phase I trial reported in the Journal of Clinical Oncology, Aditya Bardia, MD, MPH, and colleagues identified activity of the oral selective estrogen receptor (ER) degrader (SERD) elacestrant in postmenopausal women with heavily pretreated ER-positive, HER2-negative breast cancer, including...

Breast Cancer
Supportive Care
Survivorship

Expert Point of View: Shoshana Rosenberg, ScD, MPH

Shoshana Rosenberg, ScD, MPH, Assistant Professor of Medicine at Dana-Farber Cancer Institute and Harvard Medical School, Boston, weighed in on the implications of these findings. “The study underscores the importance of addressing psychosocial health in survivorship. it targeted a particularly...

Breast Cancer
Supportive Care
Survivorship

Meditation and Education Interventions May Improve Depressive Symptoms in Young Breast Cancer Survivors

A diagnosis of breast cancer and subsequent treatment may increase the risk of depression, especially among younger women with breast cancer. A new study showed that behavioral interventions—specifically mindfulness meditation and survivorship education classes—may reduce depressive symptoms, as...

Breast Cancer
Immunotherapy

Expert Point of View: William Gradishar, MD

William Gradishar, MD, the Betsy Bramsen Professor of Breast Oncology at Northwestern University Feinberg School of Medicine and Deputy Director for the Clinical Network of the Lurie Cancer Center, commented on the findings of the ASCENT biomarker analysis in the closing panel discussion. The...

Breast Cancer
Immunotherapy

Is Trop-2 Expression Associated With Benefit From Sacituzumab Govitecan-hziy?

The antibody-drug conjugate sacituzumab govitecan-hziy (sacituzumab govitecan) is beneficial in previously treated patients with metastatic triple-negative breast cancer, irrespective of Trop-2 expression, according to a biomarker analysis of the phase III ASCENT trial.1 Although greater efficacy...

Breast Cancer
Survivorship

Study Examines Pregnancy Outcomes in Breast Cancer Survivors

Breast cancer survivors of child-bearing age appear to have a more difficult time becoming pregnant than the general population, and when they do become pregnant, they have a higher risk of preterm labor and need for cesarean section. Fortunately, most women deliver healthy babies, but they are...

Breast Cancer

Expert Point of View: Neil M. Iyengar, MD

Neil M. Iyengar, MD, Assistant Attending Physician at Memorial Sloan Kettering Cancer Center, New York, has researched the links between breast cancer and lifestyle. He provided comments on these two abstracts from the 2020 San Antonio Breast Cancer Symposium (SABCS) for The ASCO Post. “These two...

Breast Cancer

Can a High-Carbohydrate Diet Increase the Risk for Breast Cancer?

A growing body of evidence is showing a strong association between diet and breast cancer risk and survival, particularly high glycemic load and sugar intake. Two large population studies at the 2020 San Antonio Breast Cancer Symposium supported these observations.1,2 Findings from the Nurses’...

Breast Cancer
Issues in Oncology

Role of Twitter in Identifying Barriers to Care Among Patients With Metastatic Breast Cancer

Information shared by women with metastatic breast cancer on social media platforms like Twitter may be a timely source of data for policymakers hoping to improve care and outcomes for these patients, according to a study published by Shimkhada et al in JMIR Public Health and Surveillance. Role of...

Breast Cancer

Breast Cancer–Specific Mortality by Race/Ethnicity and 21-Gene Recurrence Scores

In a U.S. population–based cohort study reported in JAMA Oncology, Hoskins et al found that among patients with estrogen receptor–positive breast cancer, Black women were more likely than White women to have a high Oncotype DX 21-gene recurrence score. Researchers also found that breast...

Issues in Oncology
COVID-19
Breast Cancer
Lung Cancer
Gynecologic Cancers
Global Cancer Care

Impact of COVID-19 on Cancer Care Has Been ‘Profound,’ According to WHO

More than a year since the new coronavirus crisis began, its impact on cancer care has been stark, with “50% of governments (having) cancer services partially or completely disrupted because of the pandemic,” said André Ilbawi, MD, of the World Health Organization’s (WHO) Department of...

Breast Cancer
Immunotherapy

Margetuximab-cmkb vs Trastuzumab in Heavily Pretreated Patients With HER2-Positive Breast Cancer: SOPHIA Trial

As reported in JAMA Oncology by Hope S. Rugo, MD, and colleagues, the phase III SOPHIA trial has shown significantly prolonged progression-free survival with margetuximab-cmkb plus chemotherapy vs trastuzumab plus chemotherapy in patients with HER2-positive breast cancer who experienced disease...

Breast Cancer
Genomics/Genetics

Protein-Truncating and Rare Missense Variants in Breast Cancer Risk Genes: Association With Disease Risk

In a study reported in The New England Journal of Medicine, members of the international Breast Cancer Association Consortium (BCAC) identified the risk of disease associated with germline protein-truncating and rare missense variants of putative susceptibility genes in a large population of breast ...

Advertisement

Advertisement

Advertisement